3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Solid Tumor, Adult
1
Pyloric Stenosis, Hypertrophic
1
Nasopharyngeal Carcinoma
1
Lymphoproliferative Disorders
1
Epstein-Barr Virus Infections
1
EBV Lymphomas
1
Advanced Cancer
1
Interventions
tafasitamab
1
Valganciclovir
1
N,N-dicyclopropyl-4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo(4,5-d)pyrrolo(2,3b)pyridine-7-carboxamide
1
Lenalidomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Pyloric Stenosis, Hypertrophic
×
Valganciclovir
×
Clear all
NCT05011058
2025-07-28
NAVAL-1
Viracta Therapeutics, Inc.
Phase 2
Terminated
102 enrolled
28 charts